High-Quality Endoscopic Ultrasound-Guided Fine Needle Aspiration Tissue Acquisition

The degree of technical difficulty of EUS-FNA varies according to the location of the targeted lesion. Generally, transesophageal and transgastric FNAs are technically easier than transduodenal FNA. The position of the scope is relatively straight when accessing the majority of lesions via the esophagus or stomach. An exception is access from the gastric fundus, where near complete retroflexion may be required. Acute angulation of the tip of the scope, significant torsion through the scope shaft, and maximal elevator use increases the technical difficulty. This is predominantly an issue in the duodenum. The main challenges are passing the needle assemblage through the scope to attach to the working channel, and smoothly advancing the needle into the targeted lesion, while maintaining scope position and needle control and maneuverability. Releasing the up-down control to straighten the tip of the scope, with or without withdrawing the scope into a neutral position enables the needle to be passed and attached to the working channel, and the scope is then repositioned for the FNA. If the needle doesn’t advance into the lesion, straightening the scope from a long to a short position often reduces the scope tip angulation and the resistance to passage of the needle. A 25G needle is suitable for sampling the majority of lesions accessed from the second part of the duodenum, and a flexible 19G needle may be beneficial if histology is required [7].

EUS-FNA can be performed using a 25G, 22G, or a 19G needle. The decision to use a specific needle is guided by a number of considerations. The needle should provide an adequate tissue sample to establish a definitive diagnosis, have the degree of flexibility required for lesion access, a low risk of complications, and the ability to obtain core tissue when necessary.

A randomized trial compared the 19G and 22G needles in 117 patients with pancreatic and peripancreatic masses [11]. Superior diagnostic accuracy and tissue acquisition was obtained with the 19G needle; however, there was a high rate of technical failure for lesions in the head of pancreas. The role of the standard 19G FNA needle for yielding histological samples was prospectively assessed in a single-arm study by Larghi et al. [17]. Of the 120 patients who underwent EUS-FNA, the procedure was technically successful in 119 patients (99.2%) and adequate histological sample was obtained in 116 (97.5%) of these patients. A major limitation of the study was that patients with pancreatic head or uncinate masses were excluded. A recent multicenter randomized trial compared a flexible 19G needle made of nitinol (Flex 19; Boston Scientific, Natick, MA, USA) to a 25G needle for FNA of solid pancreatic masses [12]. While diagnostic accuracy and technical failure was similar between needles, the 19G needle yielded histological core tissue in significantly more patients (86.1% vs. 33.3%, P < 0.001).

The 19G Trucut biopsy needle (Cook Medical, Winston-Salem, NC, USA) was developed to attain core histologic tissue [18]; however, the needle’s rigidity limited its use for transduodenal sampling [19]. A new 19G fine needle biopsy (FNB) device (ProCore; Cook Medical, Winston-Salem, NC, USA) with reverse bevel technology was subsequently developed. Histological samples were successfully obtained in a majority of patients with a diagnostic accuracy of >90% [20], however, some technical difficulties were encountered with transduodenal passes. 22G and 25G ProCore needles are also available, which facilitate transduodenal sampling. Three recent randomized trials comparing the 22G or 25G ProCore needles to standard FNA needles in pancreatic masses and peripancreatic lymphadenopathy [21, 22, 23] have concluded that there is no significant difference in establishing a correct diagnosis between needles. In a study using the 25G ProCore needle, while a cytological diagnosis was established in 96% of 50 patients, histological core tissue was procured in only 32% of patients [22]. A study in 144 patients using the 22G ProCore needle vs. a standard 22G FNA needle showed similar diagnostic accuracy between needles, and fewer passes were required to obtain sufficient tissue with the ProCore needle (1.2 ± 0.5 passes with ProCore vs. 2.5 ± 0.9 passes with standard needle, P < 0.001) [23].

The safety profile of EUS-FNA is excellent [40, 41]. The majority of complications are encountered during aspiration of cystic lesions, and prophylactic antibiotics are recommended to reduce the risk of sepsis [40]. Clinically significant intracystic hemorrhage is rare and bleeding usually resolves spontaneously. Low-dose aspirin can be safely continued, but clopidogrel must be stopped 7 days prior to EUS-FNA. Low-molecular weight heparin and unfractionated heparin must be discontinued 12–24 and 6 h prior to FNA, respectively. Warfarin should be withheld 5 days before in low-risk patients, and bridged with heparin in patients at high risk for thrombotic events [42]. A systematic review concluded that there is a low risk of pancreatitis following pancreatic EUS-FNA, at 0.44% [43]. A recent meta-analysis comparing rates of complications between standard 19G and 22G/25G needles for pancreatic EUS-FNA [44] showed no significant difference in rates of pancreatitis, bleeding, infection, perforation, or abdominal pain. Experience with the 19G needle for FNA is limited, and its safety profile will become more defined with increased use.

There is a learning curve for performing EUS-FNA. While recommendations of the number of supervised EUS-FNAs vary [24, 45, 46, 47], competence in linear EUS is essential before commencing FNA. Two learning curve studies have been performed, both in pancreatic masses. In a study of 57 patients who underwent EUS-FNA by a self-taught endosonographer, the diagnostic sensitivities for malignancy from the first to the last 10 quintiles were 30%, 40%, 70%, 90%, and 80%, respectively [48]. In second study of 300 consecutive patients who underwent EUS-FNA by a trained endosonographer, the median number of passes required to establish a diagnosis decreased significantly with operator experience but without any difference in diagnostic accuracy [49]. This suggests that while the diagnostic accuracy may plateau over time, the procedural expertise continues to improve with experience.

The success of EUS-FNA is largely dependent upon the experience and technique of the endosonographer, as well as the proficiency and diagnostic experience of the pathologist (Fig. 1) [50]. The presence of on-site cytopathology increases the diagnostic accuracy of the procedure while decreasing the number of inadequate and suboptimal specimens [51]. The nondiagnostic rate has been reported as low as 1% for FNAs with rapid on-site evaluation (ROSE) as compared with 20% without ROSE [52]. This is particularly important, as specimens obtained by EUS-FNA are often the only histologic proof of malignancy, permitting tissue-based (immunohistochemical, molecular, and genomic) testing for optimal patient management. A recent meta-analysis showed that ROSE was associated with a 10% higher tissue adequacy rates on average, but had no impact on diagnostic accuracy [53].

Open image in new window

ROSE is not available at many centers secondary to the considerable time commitment, cost, and inadequate reimbursement or compensation by insurance or medicare. This has led to practices relying upon either endoscopy nurses, technologists, and/or endosonographers to independently handle, collect, and evaluate aspirated material. Many practices have attempted to avoid the need of on-site evaluation by performing FNB and/or core needle biopsy. However, regardless of the modality used, the sample obtained will be limited in size and cellular yield. Therefore, the independent endosonographer may benefit from knowing the basic cytopathologic techniques for handling and processing tissue to optimize the specimens sent for off-site evaluation [54].

The most important factor in handling, processing, and evaluating the procured tissue is consistency. Having one dedicated person handling the aspirated material establishes a protocol for preparation and minimizes the artifacts of improper tissue handling and collection. In addition, the level of independence must be defined. Cytopathology assistance can be on-site, at a close proximal location, or remote (telepathology) assistance. Therefore, the independent endosonographer should be aware of the operational structure of their EUS center and thereby the supplies and equipment required for correct specimen handling.

While most endosonographers do not routinely practice in-room basic cytomorphology analysis, a study has shown that microscopic evaluation of smears by independent practitioners (with basic cytomorphology training) without access to on-site assistance significantly improves diagnostic accuracy [55]. Short intensive EUS-cytopathology courses for endosonographers have also been shown to provide effective training in specimen handling and evaluation for diagnostic adequacy [56]. Integrating focused EUS-cytopathology didactics into advanced endoscopy fellowships has been suggested, knowing that many newly trained graduates join practices without cytopathology support. This is becoming increasingly common as changes in medical reimbursement, such as bundled payments, changes in capitations, and global budgets, are taking place.

Many cytotechnologists and pathologists utilize gross visible assessment as a valuable mechanism to determine if cellular material has been obtained and to reduce procedural time. The slide that macroscopically appears to be cellular is evaluated first under the microscope. This may allow a diagnosis to be reached more quickly, minimize the number of unnecessary passes, and allow for diagnostic material to be diverted to cell block. In addition to gross assessment of smears, experienced personnel who routinely handle the aspirated material become adept in evaluating core biopsy specimens and aspirated material collected in solution for ancillary testing, and may come to recognize bloody, dilute, sclerotic, and mucoid samples based upon the consistency and manner that the material extrudes from the needle. As an example, both sclerotic and necrotic material may appear tan-white in color, but sclerotic stromal tissue is firm, not easily smeared, and as a core may sink to the bottom of the collection tube. Likewise, the experienced eye often can discriminate between red hemorrhagic “core” tissue, and tan-pink material that has a higher diagnostic yield. Gross visual assessment is not equivalent to microscopic evaluation, but with experience personnel can readily predict an inadequate specimen [57]. This can be invaluable, particularly when determining if sufficient material has been collected for cell block.

Cell block is often the best material for ancillary testing. With concurrent advances in minimally invasive procedures and molecular diagnostics, cell blocks are often required for multiple tissue sections for immunohistochemical and special staining, molecular testing, and research. Cell blocks typically maintain architectural integrity, so can be compared to other tissue specimens in a given patient. There is no standard method for cell block preparation, and multiple methods may exist even within a single institution. The quality and cellular yield of the more commonly used methods of cell block preparation, such as plasma-thrombin, histogel, or Cellient™ (Hologic, Inc.; Bedford, MA, USA) technology can be unsatisfactory [58]. Until the cell block preparation method is optimized, the responsibility of collecting enough material for a diagnostic cell block remains with the endoscopist.

Minimally invasive tissue acquisition is a powerful tool, and the role of EUS-FNA will continue to expand and evolve with technical advances in needle and scope design, and integration of cytopathology training and diagnostics. Tissue acquisition relies upon lesion access, which is particularly challenging from the duodenum when an unstable or acutely angulated scope position may be required. This can be improved by addressing the two key limiting factors: needle and scope design. Needles require flexibility to smoothly pass through the scope and into the lesion, and respond to manipulation with the scope tip and elevator to sample in different trajectories through the lesion. Further advances in scope design may include developing a thinner, more flexible scope with increased range of movement at the tip of the scope. Such changes may also improve the safety of passing the scope through the pharynx and from the first to second part of the duodenum. Integration of a mechanism to provide variable stiffness through the shaft of the scope, analogous to colonoscopes, may also increase the scope stability and functionality. Development of a scope capable of performing both EUS and endoscopic retrograde cholangiopancreatography, to allow combined procedures without exchanging scopes, would be a game changer. Essential to EUS performance is the quality of ultrasound imaging, and further advances include expanding the angle of EUS imaging and increasing image resolution. Finally, the march toward in-room pathology diagnosis continues, and providing high-quality EUS-FNA specimens is the first step. Integration of basic cytopathology training and utilization is the next step, and in the future this may be followed by an increased shift of pathological evaluation from the laboratory into the endoscopy room to allow real-time diagnosis.